Treatment Study for Newly Diagnosed High Risk B-Lymphoblastic Leukemia in Patients with Ph-like TKI Sensitive Mutations

Clinical Trial Title

A phase III randomized trial for newly diagnosed high risk B-lymphoblastic leukemia (B-ALL) including a stratum evaluating dasatinib (IND#73789, NSC#732517) in patients with Ph-like tyrosine kinase inhibitor (TKI) sensitive mutations.

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

To determine if the administration of post-induction age adjusted intrathecal triple chemotherapy on an chemotherapy backbone will  improve 5-year DFS of children with high risk B-ALL compared to age adjusted intrathecal methotrexate.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are more than 365 days old and less than 31 years of age.
  • White blood cell count (WBC) criteria:
    • Are 1 to 9.99 years of age: WBC of 50,000/µL
    • Are 10 to 30.99 years of age: Any WBC
    • Are 1 to 30.99 years of age: Any WBC with:
      • Testicular leukemia
      • CNS leukemia (CNS3)
      • Steroid pretreatment

This is a partial list of eligibility requirements.

Study Details

Clinical Trial Investigator

Mary Lou Schmidt, MD

Contact Information

Rush Cancer Center Clinical Trials Office


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more